{"id":58308,"date":"2026-02-27T20:04:01","date_gmt":"2026-02-27T12:04:01","guid":{"rendered":"https:\/\/flcube.com\/?p=58308"},"modified":"2026-02-27T20:04:03","modified_gmt":"2026-02-27T12:04:03","slug":"kanghong-pharmas-orexin-antagonist-khn707-cleared-for-insomnia-trials-first-in-class-sleep-disorder-candidate","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58308","title":{"rendered":"Kanghong Pharma&#8217;s Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate"},"content":{"rendered":"\n<p><strong>Chengdu Kanghong Pharmaceutical Group Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/002773:SHE\">SHE:\u202f002773<\/a>)<\/strong> announced receiving <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>KHN707 tablets<\/strong>, a <strong>Category\u202f1 chemical drug<\/strong> for the treatment of <strong>insomnia<\/strong>. The <strong>selective orexin\u202f2 receptor (OX2R) antagonist<\/strong> represents a <strong>novel mechanism<\/strong> in sleep medicine, with preclinical data showing <strong>promising therapeutic effects<\/strong> and <strong>favorable safety profiles<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:\u202f002773)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>KHN707 tablets<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category\u202f1 innovative chemical drug<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA clinical trial approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Insomnia<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Selective orexin\u202f2 receptor (OX2R) antagonist<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>Preclinical completed; Phase I initiation pending<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-khn707\">Drug Profile \u2013 KHN707<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td><strong>Orexin\u202f2 receptor (OX2R)<\/strong> \u2013 neuropeptide receptor regulating wakefulness and arousal<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td>Selective OX2R antagonist<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Blocks orexin\u2011mediated wakefulness signals \u2192 promotes sleep onset and maintenance<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td><strong>Selective OX2R<\/strong> targeting vs. dual OX1R\/OX2R antagonists (e.g., suvorexant)<\/td><\/tr><tr><td><strong>Preclinical Profile<\/strong><\/td><td>Good safety; promising efficacy in insomnia models<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel Sleep Mechanism:<\/strong> Orexin antagonism represents a <strong>next\u2011generation insomnia treatment approach<\/strong>, distinct from <strong>GABA\u2011A modulators<\/strong> (benzodiazepines, Z\u2011drugs) with abuse liability and next\u2011day impairment risks.<\/li>\n\n\n\n<li><strong>Selective OX2R Advantage:<\/strong> KHN707&#8217;s <strong>OX2R selectivity<\/strong> may offer <strong>improved safety<\/strong> vs. dual orexin antagonists, potentially reducing <strong>suicidality and next\u2011day somnolence<\/strong> concerns associated with broader orexin pathway inhibition.<\/li>\n\n\n\n<li><strong>China Insomnia Market:<\/strong> Sleep disorders affect <strong>hundreds of millions in China<\/strong>; existing therapies have significant limitations, creating demand for <strong>mechanistically novel alternatives<\/strong> with better safety profiles.<\/li>\n\n\n\n<li><strong>Kanghong Innovation Pivot:<\/strong> NMPA approval validates Kanghong&#8217;s <strong>CNS drug discovery capabilities<\/strong>, diversifying beyond its established <strong>ophthalmology franchise<\/strong> (conbercept).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Orexin Market<\/strong><\/td><td>Suvorexant (Belsomra) established proof\u2011of\u2011concept; daridorexant (Quviviq) approved 2022; selective OX2R programs in development<\/td><\/tr><tr><td><strong>China Sleep Market<\/strong><\/td><td>Rapidly growing; traditional Chinese medicine and Z\u2011drugs dominate; orexin antagonists represent premium segment opportunity<\/td><\/tr><tr><td><strong>Regulatory Environment<\/strong><\/td><td>NMPA Category\u202f1 approval supports innovative CNS development; insomnia trials have established endpoints (polysomnography, patient\u2011reported outcomes)<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Limited orexin programs in China; KHN707 first\u2011mover advantage in domestic OX2R\u2011selective space<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase I initiation, safety confirmation, and efficacy validation for KHN707. Actual results may differ due to risks including first\u2011in\u2011human tolerability, competitive orexin program advancements, and insomnia trial recruitment challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u5eb7\u5f18\u836f\u4e1a\uff1a\u5173\u4e8e\u516c\u53f8\u6536\u5230\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u5eb7\u5f18\u836f\u4e1a\uff1a\u5173\u4e8e\u516c\u53f8\u6536\u5230\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-cc818c93-4b8a-4cfa-8ee1-5a9698d7c39d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u5eb7\u5f18\u836f\u4e1a\uff1a\u5173\u4e8e\u516c\u53f8\u6536\u5230\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u5eb7\u5f18\u836f\u4e1a\uff1a\u5173\u4e8e\u516c\u53f8\u6536\u5230\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u5eb7\u5f18\u836f\u4e1a\uff1a\u5173\u4e8e\u516c\u53f8\u6536\u5230\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-cc818c93-4b8a-4cfa-8ee1-5a9698d7c39d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:\u202f002773) announced receiving clinical trial approval from China&#8217;s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,653,1335],"class_list":["post-58308","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-kanghong-pharmaceutical","tag-she-002773"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kanghong Pharma&#039;s Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:\u202f002773) announced receiving clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for KHN707 tablets, a Category\u202f1 chemical drug for the treatment of insomnia. The selective orexin\u202f2 receptor (OX2R) antagonist represents a novel mechanism in sleep medicine, with preclinical data showing promising therapeutic effects and favorable safety profiles.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58308\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kanghong Pharma&#039;s Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate\" \/>\n<meta property=\"og:description\" content=\"Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:\u202f002773) announced receiving clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for KHN707 tablets, a Category\u202f1 chemical drug for the treatment of insomnia. The selective orexin\u202f2 receptor (OX2R) antagonist represents a novel mechanism in sleep medicine, with preclinical data showing promising therapeutic effects and favorable safety profiles.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58308\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-27T12:04:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-27T12:04:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58308#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58308\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kanghong Pharma&#8217;s Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate\",\"datePublished\":\"2026-02-27T12:04:01+00:00\",\"dateModified\":\"2026-02-27T12:04:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58308\"},\"wordCount\":398,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Kanghong Pharmaceutical\",\"SHE: 002773\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58308#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58308\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58308\",\"name\":\"Kanghong Pharma's Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-27T12:04:01+00:00\",\"dateModified\":\"2026-02-27T12:04:03+00:00\",\"description\":\"Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:\u202f002773) announced receiving clinical trial approval from China's National Medical Products Administration (NMPA) for KHN707 tablets, a Category\u202f1 chemical drug for the treatment of insomnia. The selective orexin\u202f2 receptor (OX2R) antagonist represents a novel mechanism in sleep medicine, with preclinical data showing promising therapeutic effects and favorable safety profiles.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58308#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58308\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58308#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kanghong Pharma&#8217;s Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kanghong Pharma's Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate - Insight, China&#039;s Pharmaceutical Industry","description":"Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:\u202f002773) announced receiving clinical trial approval from China's National Medical Products Administration (NMPA) for KHN707 tablets, a Category\u202f1 chemical drug for the treatment of insomnia. The selective orexin\u202f2 receptor (OX2R) antagonist represents a novel mechanism in sleep medicine, with preclinical data showing promising therapeutic effects and favorable safety profiles.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58308","og_locale":"en_US","og_type":"article","og_title":"Kanghong Pharma's Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate","og_description":"Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:\u202f002773) announced receiving clinical trial approval from China's National Medical Products Administration (NMPA) for KHN707 tablets, a Category\u202f1 chemical drug for the treatment of insomnia. The selective orexin\u202f2 receptor (OX2R) antagonist represents a novel mechanism in sleep medicine, with preclinical data showing promising therapeutic effects and favorable safety profiles.","og_url":"https:\/\/flcube.com\/?p=58308","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-27T12:04:01+00:00","article_modified_time":"2026-02-27T12:04:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58308#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58308"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kanghong Pharma&#8217;s Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate","datePublished":"2026-02-27T12:04:01+00:00","dateModified":"2026-02-27T12:04:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58308"},"wordCount":398,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Kanghong Pharmaceutical","SHE: 002773"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58308#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58308","url":"https:\/\/flcube.com\/?p=58308","name":"Kanghong Pharma's Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-27T12:04:01+00:00","dateModified":"2026-02-27T12:04:03+00:00","description":"Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:\u202f002773) announced receiving clinical trial approval from China's National Medical Products Administration (NMPA) for KHN707 tablets, a Category\u202f1 chemical drug for the treatment of insomnia. The selective orexin\u202f2 receptor (OX2R) antagonist represents a novel mechanism in sleep medicine, with preclinical data showing promising therapeutic effects and favorable safety profiles.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58308#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58308"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58308#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kanghong Pharma&#8217;s Orexin Antagonist KHN707 Cleared for Insomnia Trials \u2013 First-in-Class Sleep Disorder Candidate"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58308"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58308\/revisions"}],"predecessor-version":[{"id":58310,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58308\/revisions\/58310"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}